CNS Tumor Clinical Trial
Official title:
Phase II Study of Antineoplastons A19 and AS2-1 in Patients With Neurofibroma and Schwannoma
RATIONALE: Current therapies for adults with a recurrent/residual Neurofibroma or Schwannoma
provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy
suggest that it may prove beneficial in the treatment of adults with a recurrent/residual
Neurofibroma or Schwannoma.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on adults with a recurrent/residual Neurofibroma or Schwannoma.
OVERVIEW: This is a single arm, open-label study in which adults with a recurrent/residual
Neurofibroma or Schwannoma receive gradually escalating doses of intravenous Antineoplaston
therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment
continues for at least 12 months in the absence of disease progression or unacceptable
toxicity.
OBJECTIVES:
- To determine the efficacy of Antineoplaston therapy in adults with a recurrent/residual
Neurofibroma or Schwannoma, as measured by an objective response to therapy (complete
response, partial response or stable disease).
- To determine the safety and tolerance of Antineoplaston therapy in adults with a
recurrent/residual Neurofibroma or Schwannoma.
- To determine objective response, tumor size is measured utilizing MRI scans, which are
performed every 8 weeks for the first two years, every 3 months for the third and fourth
years, every 6 months for the 5th and sixth years, and annually thereafter.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued to this study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06036394 -
Artificial Intelligence in CNS Radiation Oncology
|
||
| Withdrawn |
NCT05222165 -
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03838042 -
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05300113 -
Artificial Intelligence Neuropathologist
|
||
| Completed |
NCT04334239 -
Effectiveness of Care in Certified Cancer Centres in Germany
|
||
| Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
| Withdrawn |
NCT05952687 -
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
|
Phase 1 | |
| Recruiting |
NCT06322342 -
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
|
Phase 2 | |
| Not yet recruiting |
NCT06441331 -
Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
|
Phase 1 | |
| Recruiting |
NCT04706676 -
Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer
|
N/A | |
| Recruiting |
NCT04773782 -
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04023669 -
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT05982691 -
Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors
|
||
| Recruiting |
NCT04732065 -
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02684838 -
Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry
|
||
| Recruiting |
NCT05480904 -
Characterizing Sleep Among Long-term Survivors of Childhood Cancer
|